UNSPSC 51272708: Methionine sulfoxide

This classification denotes a dietary amino acid with the molecular formula C5H11NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XN1XVI4B2C, chemically known as butanoic acid, 2-amino-4-(methylsulfinyl)-, (2s)-, but more generally known as methionine sulfoxide, which bears US NIH Compound Identifier 847. European Medicines Agency schedules methionine sulfoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08850MIG.

Most nations, for tariff purposes, schedule methionine sulfoxide under HS 29304010. SMILES: C[S+](CC[C@@H](C(=O)O)N)[O-].

UNSPSC 51272708 Methionine sulfoxide is a Commodity code that nominally identifies individual amino acid derivatives, but recent state and local procurement activity under this code does not reflect purchases of methionine sulfoxide itself. Instead, the code appears in solicitations for naloxone and safe drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescription programs (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's chemical scope and the actual procurement activity suggests either a tagging error in the underlying opportunities or that this code is being applied broadly to pharmaceutical and health-related goods beyond its defined commodity. The issuing bodies span county health departments, state health agencies, and cooperative purchasing consortia, reflecting the multitiered geography of state and local health procurement.

Geographic activity appears concentrated in the South and Upper Midwest, with recent solicitations from Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the posted date and response deadline are inconsistent in the source). Texas HHS issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription fulfillment programs. The Minnesota Department of Administration's Office of State Procurement, through MMCAP, posted an RFP (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The code shows limited recent activity and presents a poor fit with its stated definition; firms should verify tagging accuracy with issuing bodies before pursuing opportunities marked under this code.